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ABSTRACT
Tumor-associated alterations in RNA splicing result either from mutations in splicing-regulatory elements or changes in
components of the splicing machinery. This review summarizes our current understanding of the role of splicing-factor
alterations in human cancers. We describe splicing-factor alterations detected in human tumors and the resulting changes in
splicing, highlighting cell-type-specific similarities and differences. We review the mechanisms of splicing-factor regulation in
normal and cancer cells. Finally, we summarize recent efforts to develop novel cancer therapies, based on targeting either the
oncogenic splicing events or their upstream splicing regulators.
INTRODUCTION
We have known for many years that tumors exhibit abnormal
splicing patterns, compared to normal tissues. Changes in
splicing occur for genes involved in every step of the transfor-
mation process (for review, see David et al. 2010). For exam-
ple, the increased expression of anti-apoptotic isoforms of
genes such as BCL2L1, CASP2, or FAS, has been extensively
documented in various tumors types; alternative splicing of
CD44, FGFR2, RAC1, orMST1R has been linked with the ac-
quisition of invasive properties; and VEGFA splice variants
are involved in angiogenesis regulation (Fig. 1). However,
in the past few years we have started to appreciate that
many of these tumor-associated splicing changes reflect alter-
ations in particular components of the splicing machinery
(Fig. 1). The core spliceosome plus associated regulatory fac-
tors comprise more than 300 proteins and five small nuclear
RNAs (snRNAs), and catalyzes both constitutive and regulat-
ed alternative splicing (Hegele et al. 2012). The U1, U2, U4,
U5, and U6 snRNAs participate in several key RNA–RNA and
RNA–protein interactions during spliceosome assembly and
splicing catalysis. These snRNAs associate with seven “Sm”
core proteins and additional proteins to form small nuclear
ribonucleoprotein particles (snRNPs). Other protein sub-
complexes also play key roles, such as the SF3A and B com-
plexes, and the PRP19-associated complexes dubbed NTC
and NTR. The architecture of the spliceosome undergoes ex-
tensive remodeling in preparation for, during, and after splic-
ing. In addition to the core spliceosome, regulatory proteins
are involved in modulating the splicing reaction. These in-
clude RNA-binding proteins that function as activators or re-
pressors of splicing by binding specifically to exonic or
intronic enhancer or silencer elements, respectively, and
they are involved in both constitutive and alternative splicing
(for review, see Biamonti et al. 2014). In this review, we dis-
cuss the various splicing-factor alterations detected in human
tumors, their cell-type specificity, as well as their specific
roles in tumor development and progression.
RECURRENT SOMATIC MUTATIONS OF CORE
SPLICEOSOME COMPONENTS IN HEMATOLOGICAL
MALIGNANCIES
Recently, large-scale sequencing projects identified recurrent
somatic mutations in certain components of the spliceosome
in several types of hematological malignancies, includ-
ing myelodysplastic syndromes (MDS), other myeloid neo-
plasms, and chronic lymphocytic leukemia (CLL) (Table 1;
Yoshida et al. 2011; Bejar et al. 2012; Papaemmanuil et al.
2013). These mutations occur most commonly in four genes:
SF3B1 (splicing factor 3b subunit 1), SRSF2 (serine/arginine-
rich splicing factor 2), U2AF1 (U2 small nuclear RNA auxil-
iary factor 1), and ZRSR2 (zinc finger RNA binding motif
and serine/arginine rich 2), and almost always as somatic het-
erozygous missense mutations that are mutually exclusive
(Papaemmanuil et al. 2011; Wang et al. 2011; Yoshida et al.
2011). In a very detailed review, Yoshida and Ogawa (2014)
discussed the discovery of splicing-factor mutations and their
correlation with tumor classification. Here we will focus on
the functional differences and similarities between mutant
splicing factors in hematological malignancies.
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SFB3B1—splicing factor 3b subunit 1
SF3B1, the most frequently mutated component of the spli-
ceosome in cancer, is involved in the recognition of the
intronic branch point sequence (BPS) during selection of
the 3′ splice site (3′SS) (Fig. 2). SF3B1 is a component of
the SF3B complex, which associates with the SF3A complex
and U2 snRNP to form the 17SU2 complex. U2 snRNP binds
to BPSs via SF3B14, and to U2AF2 via SF3B1 to stabilize the
base-pairing interaction between U2 snRNA and the BPS,
leading to the formation of the spliceosomal A complex.
SF3B1mutations are found in a variety of myeloid malignan-
cies, with extremely high recurrence (48%–57%) in MDS
subtypes that show increased ring sideroblasts (RARS/
RCMD-RS) (Malcovati et al. 2011; Yoshida et al. 2011;
Damm et al. 2012; Patnaik et al. 2012; Visconte et al.
2012), as well in 6%–26% of CLLs (Table 1). SF3B1 muta-
tions are clustered in several hot spots, including K700,
E622, R625, H662, and K666, all of which are located within
HEAT (Huntingtin, Elongation factor 3, protein phosphatase
2A, Targets of rapamycin 1) repeats that extend from exon
12 to exon 15 (Fig. 2). In addition, SF3B1 mutations of resi-
dues K700 and K666 have been reported in 1.8% of unselect-
ed breast tumors and 4% of luminal breast tumors (Ellis et al.
2012; Maguire et al. 2015), as well as in 3% of pancreatic duc-
tal adenocarcinomas (Biankin et al. 2012), whereas muta-
tions of residues R625 and K666 are found in 15%–29% of
uveal melanomas (Furney et al. 2013;
Harbour et al. 2013; Martin et al. 2013)
and 1% of cutaneous melanomas (Table
1; Kong et al. 2014).
SF3B1 mutations correlate with good
prognosis in MDS and melanoma, but
with poor prognosis in CLL. The SF3B1
K700 mutant promotes utilization of
a different BPS compared to wild-type
SF3B1, and recognizes a cryptic 3′SS
with a short and weak polypyrimidine
tract, located upstream of the canonical
3′SS (Darman et al. 2015). Similarly,
SF3B1 R625 and K666 mutations result
in deregulated splicing at a subset of
splice sites, mostly involving the use of al-
ternative or cryptic 3′SS (DeBoever et al.
2015; Alsafadi et al. 2016).
SRSF2—serine/arginine-rich
splicing factor 2
The second most frequently mutated
splicing regulator in MDS is SRSF2, a
member of the serine–arginine (SR) pro-
tein family, which is involved in both
constitutive and alternative splicing.
SRSF2 bound to an exon plays a role in
recruiting U2AF to the upstream 3′SS and U1 snRNP to
the downstream 5′SS (Fig. 2). SRSF2 mutations and inser-
tions/deletions map to a unique hotspot centered on residue
P95, within the region linking the N-terminal RNA recogni-
tion motif (RRM) and the C-terminal RS domain (Fig. 2).
Recurrent SRSF2 mutations have been found in various he-
matological malignancies (Table 1), with higher frequencies
in patients with MDS (20%–30%) and chronic myelomono-
cytic leukemia (CMML) (50%) (Yoshida et al. 2011;
Papaemmanuil et al. 2013). SRSF2 mutations correlate with
poor prognosis, thus suggesting a major functional difference
compared to SF3B1 mutations. In addition, no recurrent
SRSF2 mutations have been reported to date in solid tumors.
Conditional expression from the endogenous murine
locus of the Srsf2P95H allele in the bone marrow leads to im-
paired hematopoietic differentiation in heterozygous ani-
mals; in addition, mice heterozygous for the Srsf2P95H allele
have distinct hematopoietic defects, compared to animals
with heterozygous or homozygous deletion of Srsf2 (Kim
et al. 2015). SRSF2 mutations are associated with changes
in mRNA splicing patterns of key hematopoietic regulators,
both in primary murine and patient samples, such as EZH2
and BCOR (Kim et al. 2015). The mutant SRSF2 protein ex-
hibits altered RNA-binding specificity, rather than a loss of
RNA-binding activity (Kim et al. 2015). Wild-type SRSF2 re-
cognizes the consensus binding motifs CCNG and GGNG
with similar affinity, whereas SRSF2P95H preferentially binds
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FIGURE 1. Splicing-factor alterations in human tumors. Human tumors exhibit somatic muta-
tions in splicing regulators, or changes in splicing-factor levels in response to cell signaling or
transcriptional regulation. These alterations in splicing factors promote differential splicing pat-
terns in tumors compared to normal tissues. Alterations in alternative splicing events lead to the
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CCNG, which is present within exons that are differentially
spliced. The altered interaction of mutant SRSF2 with RNA
is due to themutations affecting the conformations of the ter-
mini of SRSF2′s RRM domain, as deduced fromNMR exper-
iments (Kim et al. 2015).
U2AF1—U2 small nuclear RNA auxiliary factor
U2AF1mutations are detected in 5%–15% of MDS and 5%–
17% of CMML, as well as at lower rates in other hematolog-
ical malignancies (Table 1). They are also found in 3% of lung
tumors (Imielinski et al. 2012). The mutations are clustered
in two hotspots centered on residues S34 and Q157, located
within the two conserved zinc-finger domains (Fig. 2;
Yoshida et al. 2011). U2AF is a heterodimer involved in
3′SS selection, with the small subunit, U2AF1 interacting
with the AG dinucleotide, and the large subunit, U2AF2 in-
teracting with the polypyrimidine tract. The MDS mutations
in U2AF1 alter RNA splicing and promote mis-splicing
of genes in ways that presumably contribute to abnormal
hematopoiesis (Graubert et al. 2012; Quesada et al. 2012;
Przychodzen et al. 2013; Brooks et al. 2014; Ilagan et al.
2015; Okeyo-Owuor et al. 2015; Shirai et al. 2015).
ZRSR2—zinc finger RNA binding motif
and serine/arginine rich 2
In contrast to the above mutations, ZRSR2mutations are dis-
tributed evenly across the gene sequence, and most of them
disrupt the translational reading frame. This mutation pat-
tern suggests loss of function, rather
than gain/change of function, for the
ZRSR2mutations in MDS. ZRSR2muta-
tions are less frequent in MDS or in
CMML than SF3B1, U2AF1, or SRSF2
mutations (Table 1). ZRSR2 associates
with the U2AF heterodimer and plays a
role in 3′SS recognition by participating
in the formation of the spliceosomal
A complex (Fig. 2). shRNA-mediated
knockdown (KD) of ZRSR2 does not af-
fect splicing of U2-type introns, but leads
to the retention of U12-type introns
(Madan et al. 2015), an atypical minor
class of introns which are distinct from
the canonical U2-dependent introns
and represent only ∼0.5% of all human
introns (for review, see Turunen et al.
2013).
Other RNA-binding proteins
Finally, alterations in other RNA-binding
proteins have been reported at very low
frequencies (0.5–1.5%) in hematological
malignancies, such as de novo AML, CLL, or MDS, includ-
ing mutations in PRPF8, SF3A1, LUCL7L2, SF1, U2AF2,
HNRNPK, SRSF6, SRSF1, SRSF7, TRA2β, SRRM2, DDX1,
DDX23, CELF4 (Makishima et al. 2012; Quesada et al.
2012; The Cancer Genome Atlas Research Network 2013;
Walter et al. 2013). The existence of such mutations sug-
gests that alterations in multiple steps of spliceosome assem-
bly and splicing regulation can contribute to hematological
malignancies.
ALTERATIONS IN SPLICING-FACTOR LEVELS
IN SOLID TUMORS
Interestingly, very few recurrent mutations in splicing regula-
tors have been detected to date in solid tumors, suggesting
a fundamental difference in splicing targets and/or regulation
in hematological malignancies compared to solid tumors.
Mutations in SF3B1 (located on Chr. 2q33) have been report-
ed in 1.8% of breast tumors, and more specifically in 4% of
a subset of luminal breast tumors (Ellis et al. 2012; Maguire
et al. 2015), and are significantly associated with the pres-
ence of estrogen-receptor (ER)-positive tumor cells, AKT1
mutations, and distinct copy-number alterations, including
frequent chromosomal-segment gains on 16q12–q13 and
16q21–q22, and losses on 1p36–p35, 16q11–q13, and
16q21–q23 (Ellis et al. 2012; Maguire et al. 2015). SF3B1mu-
tations are also found at low frequency in pancreatic tumors
(Biankin et al. 2012), as well as melanoma (Furney et al. 2013;
Harbour et al. 2013; Martin et al. 2013; Kong et al. 2014).
U2AF1 mutations have been detected in 3% of lung tumors
GU A AGYRYYRY ESE ESS
5’SS 3’SSBPS Py-tract
U2
snRNPU1
snRNP
70K
SF3B1
U2AF2
U2AF1
SRSF2
ZRSR2
5’pre-mRNA 3’
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FIGURE 2. Recurrent splicing-factor mutations in human malignancies. Hotspot mutations in
the genes coding for splicing factors U2AF1, SRSF2, and SF3B1 detected inmyelodysplasia, as well
as other tumor types, are indicated. In contrast, ZRSR2 mutations are distributed evenly across
the gene (not shown). Domain abbreviations: (Zn) zinc finger domain, (UHM) U2AF homology
motif domain, (RS) arginine/serine-rich domain, (RRM) RNA-recognition motif, (HD) heat
domain.
Anczuków and Krainer
1288 RNA, Vol. 22, No. 9
 Cold Spring Harbor Laboratory Press on November 9, 2017 - Published by rnajournal.cshlp.orgDownloaded from 
(Imielinski et al. 2012). Interestingly, other splicing-factor
mutations recurrent in blood malignancies, i.e., in SRSF2
or ZRSR2, have not yet been detected in solid tumors.
However, solid tumors do exhibit frequent alterations in
splicing factors; these are mostly changes in levels, occurring
through changes in gene copy number and/or changes in
gene expression (Fig. 1). Several regulatory splicing factors,
such as SRSF1 (Karni et al. 2007; Anczukow et al. 2012),
SRSF3 (Jia et al. 2010), SRSF6 (Karni et al. 2007; Cohen-
Eliav et al. 2013), HNRNPA2/B1 (Golan-Gerstl et al. 2011),
or HNRNPH (Lefave et al. 2011), have oncogenic properties,
whereas other factors, including QKI (Zong et al. 2014),
RBM5, RBM6, and RBM10 (Bechara et al. 2013), act as tu-
mor suppressors (Table 2). Additional splicing regulators
are also involved in tumorigenesis, although their function
as oncogenes or tumor suppressors seems less clearly defined
and can be different across tissue types (see below) (Table 2).
These RNA-binding proteins elicit changes in alternative
splicing in a concentration-dependent manner, and, thus,
changes in their levels can alter pre-mRNA splicing of
many genes related to cancer, even in the absence of muta-
tions. Alternative splicing changes have been linked to cancer
through post-transcriptional regulation of components of
many of the cellular processes considered as “hallmarks” of
cancer, including cell proliferation, apoptosis, metabolism,
invasion, and angiogenesis. However, the biological conse-
quences of these global changes in alternative splicing are
only beginning to be unraveled. We will briefly discuss select-
ed examples of oncogenic or tumor suppressor splicing fac-
tors that have been found to contribute to cancer. For a
detailed review of oncogenic spliced isoforms, see David
and Manley (2010).
SRSF1—serine/arginine-rich splicing factor 1
The splicing factor SRSF1 (previously known as SF2/ASF)
is a prototypical SR protein involved in both constitutive
and alternative splicing, but it has also been implicated in
TABLE 2. Splicing-factor expression changes in human malignancies
Gene name
Alteration
type Tumor type Reference
SRSF1 AMP, OE Lung, colon, breast
ovary, thyroid, small intestine, kidney
Watermann et al. 2006; Karni et al. 2007;
Anczuków et al. 2012, 2015; Das et al. 2012;
Iborra et al. 2013
SRSF2 OE Ovary Fischer et al. 2004
SRSF3 KD
AMP, OE
Liver
Ovary, cervix, lung, breast, stomach, skin,
bladder, colon, liver, thyroid, kidney
Sen et al. 2015
He et al. 2004, 2011; Jia et al. 2010;
Iborra et al. 2013
SRSF5 OE Breast Huang et al. 2007
SRSF6 AMP, OE Lung, colon, breast, skin Karni et al. 2007; Cohen-Eliav et al. 2013;
Jensen et al. 2014
SRSF10 OE Colorectal Zhou et al. 2014
TRA2B OE Breast, ovary, colon, lung, cervix Fischer et al. 2004; Watermann et al. 2006;
Iborra et al. 2013; Kuwano et al. 2015
HNRNPA1 OE Breast, lung, colon, glioblastoma Fielding et al. 1999; Zhou et al. 2001a,b; Karni
et al. 2007; Golan-Gerstl et al. 2011
HNRNPA2/B1 AMP, OE Glioblastoma Golan-Gerstl et al. 2011
HNRNPH OE Glioblastoma Lefave et al. 2011
HNRNPK KD
OE
AML
Breast, esophageal squamous cell, pancreatic,
skin, colorectal, oral squamous cell
Gallardo et al. 2015
Mandal et al. 2001; Carpenter et al. 2006;
Roychoudhury and Chaudhuri 2007;
Zhou et al. 2010
HNRNPM OE Breast Xu et al. 2014
PTB OE Breast, ovary, malignant glioblastoma, colorectal
and mucosal
Jin et al. 2000; He et al. 2004,2007,2014;
Takahashi et al. 2015
ESPR1,2 OE/KD Breast, oral squamous cell carcinoma Ishii et al. 2014; Yae et al. 2012
RBFOX2 KD Ovary, breast Venables et al. 2009
QKI KD Lung adenocarcinoma, squamous cell carcinoma,
and large cell carcinoma, oral squamous cell
carcinoma, prostate
Lu et al. 2014; Zhao et al. 2014; Zong et al.
2014
RBM5 KD
OE
Lung, prostate
Breast
Oh et al. 2002; Rintala-Maki et al. 2007;
Zhao et al. 2012
RBM10 OE
Mut
Breast
Lung
Rintala-Maki et al. 2007
Imielinski et al. 2012
AMP, amplification; KD, knockdown; Mut, mutation; OE, overexpression.
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additional functions, such as regulating mRNA transcription,
stability and nuclear export, nonsense-mediated mRNA de-
cay (NMD), translation, and protein sumoylation (for re-
view, see Das and Krainer 2014). SRSF1 is an essential gene
and Srsf1-null mice are embryonic lethal (Xu et al. 2005).
Tissue-specific deletion of Srsf1 in mouse heart leads to le-
thality about 6–8 wk after birth, due to heart failure (Xu
et al. 2005). These mice have defective Ca2+ metabolism, at-
tributed to mis-splicing of the Ca2+/calmodulin-dependent
kinase IIδ (CAMKIIδ), which leads to a defective contractile
apparatus and cardiomyopathy. SRSF1 was also the first
member of the SR protein family to be identified as a
proto-oncogene, highlighting the important role of alterna-
tive splicing in tumorigenesis (Karni et al. 2007).
SRSF1 is frequently overexpressed in many solid tumors,
relative to their respective normal controls, including
tumors of the breast (13%), colon (25%), lung (25%), as
well as thyroid, small intestine, kidney, and ovarian tumors
(Watermann et al. 2006; Karni et al. 2007; Anczukow et al.
2012, 2015; Das et al. 2012; Iborra et al. 2013). Modest
SRSF1 overexpression is sufficient to promote transforma-
tion of immortal rodent fibroblasts (Karni et al. 2007), as
well as human mammary epithelial cells in vitro and in
vivo (Fig. 3; Anczukow et al. 2012). SRSF1 up-regulation in
some breast cancers is attributable to amplification of its lo-
cus as part of the Chr. 17q23 amplicon, which is associated
with breast malignancies with poor prognosis (Karni et al.
2007). In addition, SRSF1 is a direct transcriptional target
of the MYC oncoprotein, and high levels of SRSF1 are detect-
ed in MYC-expressing tumors (Anczukow et al. 2012; Das
et al. 2012). SRSF1 expression is also regulated at the level
of splicing, in response to the splicing factor Sam 68
(Valacca et al. 2010). Sam68 activity switches alternative
splicing of the SRSF1 transcript from an NMD-targeted iso-
form to the major, translatable isoform, thus resulting in an
increase in SRSF1 protein levels.
SRSF1 comprises two RRMs and a C-terminal RS domain
(Fig. 4). A structure–function dissection of the modular pro-
tein domains of SRSF1 showed that SRSF1’s role in regulating
proliferation and apoptosis during transformation involves
splicing targets recognized primarily by RRM1, and does
not require SRFS1’s activity in NMD or physical interaction
with mTOR (Anczukow et al. 2012). SRSF1 overexpression
affects specific pre-mRNA splicing events in the MST1R
(Ron) proto-oncogene and the kinases MKNK2 and S6K1,
promoting the expression of pro-oncogenic isoforms
(Ghigna et al. 2005; Karni et al. 2007; Anczukow et al.
2012). In addition, SRSF1 controls splicing of the tumor sup-
pressor BIN1 and the apoptotic factor BCL2L11 (BIM), pro-
moting the expression of isoforms that lack pro-apoptotic
activity and contribute at least in part to SRSF1’s activity in
transformation (Fig. 3; Anczukow et al. 2012). In addition,
SRSF1 regulates splicing of BCL2L1, MCL1, and CASP2 and
9, and its KD induces G2 cell-cycle arrest and apoptosis
(Li et al. 2005; Moore et al. 2010). Finally, SRSF1-regulated
splicing targets were identified by RNA-seq profiling of an
organotypic three-dimensional cell culture model that mim-
ics a context relevant to breast cancer, as well as of human
breast tumors with SRSF1 overexpression (Anczukow et al.
2015). Overexpression of the SRSF1-regulated, exon-9-in-
cluded CASC4 isoform—a target consistently observed in
the different data sets—increased proliferation and decreased
apoptosis, partially recapitulating SRSF1’s oncogenic effects
(Anczukow et al. 2015).
Interestingly, SRSF1-mediated oncogenesis appears to be
dependent on inactivation of the p53 tumor suppressor path-
way, a finding that could potentially be exploited when devel-
oping therapies against SRSF1-driven or -dependent tumors.
p53 induction is one of the primary responses to SRSF1 over-
expression in primary human andmurine fibroblasts, and re-
sults in cells entering a state of premature cellular senescence
(Fregoso et al. 2013). Briefly, SRSF1 plays a role in the nucle-
olar stress pathway, by stabilizing the interaction between ri-
bosomal protein RPL5 and the E3 ubiquitin ligase MDM2
FIGURE 3. Model for SRSF1’s roles in transformation in breast cancer.
Increased expression of SRFS1 in human tumors results from several dis-
tinct types of alterations, such as amplification of the Chr. 17q23 ampli-
con, transcriptional regulation of SRFS1 downstream from MYC, or
splicing regulation of SRSF1 pre-mRNA by Sam68. Up-regulation of
SRSF1 promotes splicing changes in target genes involved in apoptosis,
cell motility, proliferation, and other cellular functions. SRSF1 activates
splicing by binding to an exonic motif recognized by its RRM1. SRSF1
overexpression promotes expression of anti-apoptotic isoforms unable
to interact with pro-apoptotic factors, or that inhibit the action of pro-
apoptotic factors, such as MYC or members of the Bcl-2 family. In par-
allel, SRSF1 overexpression promotes expression of isoforms that stimu-
late translation and cell proliferation by increasing phosphorylation of
translation activators, such as S6 or eIF4E, or by inhibiting translational
repressors, such as 4EBP1. In addition, MYC can cooperate with SRSF1
in transformation, and has a synergistic effect in the activation of the
eIF4E pathway. By increasing proliferation and decreasing apoptosis,
SRSF1 promotes cellular transformation in mammary epithelial cells.
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(Fregoso et al. 2013). Sequestration of MDM2 in this com-
plex results in stabilization of the p53 tumor suppressor,
which then mediates the stress response. Consistent with
the stabilization of p53, increased SRSF1 expression in pri-
mary human fibroblasts decreases cellular proliferation and
eventually triggers oncogene-induced senescence.
SRSF3—serine/arginine-rich splicing factor 3
Among the other SR proteins, SRSF3 (previously known as
SRp20) is also frequently up-regulated in human tumors
(Fig. 4). SRSF3 is an essential gene: Srsf3 knockout (KO) in
mice results in an early lethal phenotype, suggesting a funda-
mental and nonredundant function for
each SR protein in embryonic develop-
ment (Jumaa et al. 1999). In human
tumors, SRSF3 is overexpressed in ovari-
an, cervical, lung, colon, breast, stomach,
skin, bladder, thyroid, liver, and kidney
cancer (He et al. 2004, 2011; Jia et al.
2010; Iborra et al. 2013), at least in part
due to copy-number changes in Chr.
6p21. Paradoxically, decreased expres-
sion of SRSF3 in human hepatocellular
carcinoma has also been observed (Sen
et al. 2015). Overexpression of SRSF3
promotes transformation on immortal
rodent fibroblasts, andKD reduces tumor
growth of HeLa cells (Jia et al. 2010).
SRSF3 has been shown to regulate splic-
ing of HIPK2, a homeodomain-inter-
acting protein, controlling the switch
between the full-length isoform and the
Δ8 isoform, which induces cell death
(Kurokawa et al. 2014). SRSF3 also plays
a role in regulating the splicing switch be-
tween the PKM2 and PKM1 isoforms of
pyruvate kinase, the key metabolic en-
zyme underlying the Warburg effect on
cancer cells (Wang et al. 2012a,b). Finally,
SRSF3 has been shown to be essential for
hepatocyte differentiation and metabolic
function in mice, by regulating splicing
of target genes involved in glucose and
lipid metabolism (Sen et al. 2013). Inter-
estingly, genetic deletion of SRSF3 in
hepatocytes causes fibrosis and the devel-
opment of metastatic hepatocellular car-
cinoma with aging (Sen et al. 2015).
SRSF6—serine/arginine-rich
splicing factor 6
SRSF6 (formerly SRp55) is overexpressed
in 50% of lung and colon tumors, as well
as in breast tumors, in part due to an amplification at the Chr.
20q12 locus (Fig. 4; Karni et al. 2007; Cohen-Eliav et al.
2013). SRSF6 protein levels are also frequently elevated in
basal-cell carcinomas, squamous-cell carcinomas, and malig-
nant melanomas (Jensen et al. 2014). SRSF6 overexpression
enhances proliferation and inhibits cell death of mouse
lung epithelial cells, whereas SRSF6 KD does not inhibit pro-
liferation, suggesting that SRSF6 is not required for proper
growth or survival of these cells, but overexpression may en-
hance proliferation by gain of function (Cohen-Eliav et al.
2013). SRSF6 is required for both tumor initiation and main-
tenance of lung cancer and colon cancer cells. In lung and co-
lon, SRSF6 regulates splicing of INSR and leads to the
FIGURE 4. Domain structure of splicing factors altered in solid tumors. The chromosomal locus
of each splicing-factor-encoding human gene is shown on the left. For each RNA-binding protein
(RBP) representative of the indicated families, the annotated protein domains or regions are
shown in the diagrams (see legend for details), along with the size (in amino acids) of the human
protein.
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production of the more mitogenic isoform of the insulin re-
ceptor (Cohen-Eliav et al. 2013). In human fibroblasts,
SRSF6 controls the splicing switch of the kinase MKNK2
and reduces the tumor suppressive isoform Mnk2a (Karni
et al. 2007). Finally, SRSF6 has a role in normal wound heal-
ing that is potentially related to its role in cancer (Jensen et al.
2014). Overexpression of SRSF6 causes skin hyperplasia in
mice by deregulating tissue homeostasis, and results in strong
up-regulation of Krt6, Krt16, Il1b, and many other wound-
healing markers. The effects of SRSF6 on wound healing as-
sayed in vitro depend on controlling splicing of the Tnc tenas-
cin-C isoforms (Jensen et al. 2014).
TRA2β—transformer 2β homolog (Drosophila)
The SR-like TRA2 proteins are conserved across the animal
kingdom, but separate gene paralogs encoding TRA2α and
TRA2β proteins evolved early in vertebrate evolution (for re-
view, see Best et al. 2014). KO experiments in mice showed
that Tra2β is essential for embryonic and brain development
(Mende et al. 2010; Roberts et al. 2014). In humans, TRA2β
expression changes in several cancers, and this factor has
been implicated in the pathology of other diseases, including
spinal muscular atrophy, Alzheimer’s disease, and fronto-
temporal dementia with Parkinsonism linked to Chr. 17
(Fig. 4; for review, see Long and Caceres 2009). TRA2β is
up-regulated in tumors of the lung, ovary, cervix, colon,
and breast (Fischer et al. 2004; Watermann et al. 2006;
Iborra et al. 2013). TRA2β up-regulation is associatedwith in-
vasive breast cancer, andmedium tohighTRA2β expression is
associated with poor prognosis in cervical cancer (Fischer
et al. 2004; Watermann et al. 2006; Iborra et al. 2013).
Although TRA2β expression is associatedwith cancer cell sur-
vival, its contribution to disease progression is still poorly un-
derstood. Up-regulation of TRA2β promotes several splicing
switches, including in CD44, which were previously asso-
ciated with tumor progression and metastasis (Watermann
et al. 2006). Another example of a TRA2β splicing target is
the nuclear autoantigenic sperm protein NASP, which is im-
portant for cell survival (Grellscheid et al. 2011). TRA2β also
regulates splicing of the estrogen receptor α, decreasing the
expression of the ERaΔ7 isoform, which correlates with a
better outcome in endometrial cancer (Hirschfeld et al.
2015). Finally, TRA2β regulates turnover of BCL2 mRNA,
in a splicing-independent fashion, by competing with miR-
204 for binding to the 3′UTR (Kuwano et al. 2015).
hnRNPA1 and hnRNPA2/B1—heterogeneous
nuclear ribonucleoprotein A1 and A2
hnRNPA1 and A2/B1 are structurally related members of the
hnRNP protein family, and are likely to play roles in cancer.
hnRNPA2/B1 are two spliced isoforms encoded by the same
gene, and B1 comprises 12 additional amino acids near the
N-terminus (Fig. 4). hnRNPs are a diverse superfamily of
abundant RNA-binding proteins expressed in most human
tissues (for review, see Chaudhury et al. 2010). The hnRNP
A/B family is a subset of hnRNP proteins, with closely related
sequences and a conserved modular structure. They regulate
alternative splicing, frequently by antagonizing SR proteins,
in part through the recognition of exonic splicing silencer
elements (Chaudhury et al. 2010). Additional functions of
these proteins in mRNA trafficking, and in replication and
transcription of cytoplasmic RNA viruses, have also been de-
scribed. Several studies have reported overexpression of
hnRNPA1 or A2/B1 in human tumors, including breast,
lung, colon, and glioblastoma (Fielding et al. 1999; Zhou
et al. 2001a,b; Karni et al. 2007; Golan-Gerstl et al. 2011).
hnRNPA2 is an oncogenic driver in glioblastoma and other
brain tumors, and its expression level is correlated with
poor prognosis (Golan-Gerstl et al. 2011). In the brain,
hnRNPA2 modulates alternative splicing and induces the ex-
pression of oncogenic isoforms of the tumor suppressors
BIN1 and WWOX, the anti-apoptotic proteins encoded by
CFLAR and CASP9, the insulin receptor gene IR, and the
MST1R proto-oncogene (Golan-Gerstl et al. 2011). Further-
more, hnRNPA1 and A2 modulate alternative splicing of the
glycolytic enzyme PKM2 in cancer cells, suggesting a role
in the regulation of tumor metabolism (Clower et al. 2010;
David et al. 2010).
hnRNPK—heterogeneous nuclear ribonucleoprotein K
In a subset of AML patients, the Chr. 9q21.32 genomic seg-
ment comprising the HNRNPK gene is specifically lost, sug-
gesting that a tumor suppressor may reside at this locus
(Fig. 4; Kronke et al. 2013). Additionally, AML patients har-
boring a partial deletion of Chromosome 9 exhibit a signifi-
cant decrease in hnRNPK protein expression (Gallardo et al.
2015). Hnrnpk KO is embryonic lethal in mice, whereas
Hnrnpk haploinsufficiency results in reduced survival, in-
creased tumor formation, genomic instability, and the de-
velopment of transplantable hematopoietic neoplasms
with myeloproliferation (Gallardo et al. 2015). Reduced
hnRNPK expression attenuates p21 activation, down-regu-
lates C/EBP levels, and activates STAT3 signaling (Gallardo
et al. 2015). Together, these data suggest that hnRNPK can
act as a tumor suppressor in hematological disorders. Con-
versely, hnRNPK was shown to be overexpressed in a variety
of cancers, including breast, esophageal squamous cell, pan-
creatic, skin, colorectal, and oral squamous cell carcinoma
(Mandal et al. 2001; Carpenter et al. 2006; Roychoudhury
and Chaudhuri 2007; Zhou et al. 2010). hnRNPK overex-
pression results in enhanced malignancy andmetastasis in vi-
tro, at least in part through alternative splicing of target genes
that regulate the extracellular matrix, cell motility, and angio-
genesis (Gao et al. 2013). hnRNPK also regulates splicing of
the anti-apoptoticCFLAR inhibitory protein and the vascular
endothelial growth factor VEGF in cancer cells (31, 32). Sev-
eral studies suggested that increased hnRNPK expression
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results in a potential oncogenic effect through regulation of
c-Myc in solid tumors (Notari et al. 2006; Roychoudhury
and Chaudhuri 2007), thus suggesting a fundamental differ-
ence between hnRNPK’s activity in solid tumors versus he-
matological malignancies.
PTB—polypyrimidine tract-binding protein
PTB (also known as hnRNPI), is an RNA-binding protein
that binds preferentially to pyrimidine-rich sequences (Fig.
4). PTB expression levels are significantly up-regulated in
breast, ovarian, glioblastoma, colorectal, and mucosal can-
cerous tissues compared with the corresponding normal tis-
sues (Jin et al. 2000; He et al. 2004, 2007, 2014; Takahashi
et al. 2015). PTB controls alternative splicing of target genes,
such as pyruvate kinase PKM2 (Clower et al. 2010), fibroblast
growth factor receptor-1α-exon FGFR-1 (Jin et al. 2000), and
multidrug resistance protein 1 (MRP1), which contributes to
the drug-resistance phenotype associated with many cancers
(He et al. 2004). PTB levels are elevated in cancer cell lines, as
well as endometrial tumor tissues, compared to normal tis-
sues, although no correlation was observed between PTB ex-
pression and tumor grading (Wang et al. 2008). PTB is also
overexpressed in most ovarian tumors, compared with
matched normal tissue, and its overexpression is associated
with an increased number of expressed MRP1 spliced iso-
forms (He et al. 2004, 2007). Furthermore, PTB KD decreases
breast and ovarian tumor cell proliferation, anchorage-inde-
pendent growth, and invasiveness in vitro (He et al. 2007,
2014), and is accompanied by an increased ratio of PKM1
versus PKM2 isoform and increased oxygen consumption
(He et al. 2014). PTB overexpression also enhances anchor-
age-dependent growth of immortalized human mammary
epithelial cells (HMECs) (He et al. 2014); however, overex-
pression of PTB alone is not sufficient to transform murine
fibroblasts (Wang et al. 2008). Together, these results suggest
that PTB plays a role in breast tumorigenesis.
Other hnRNPs
hnRNPM expression is associated with aggressive breast can-
cers and correlates with increased expression of the CD44
standard (CD44s) splice isoform, which comprises exons
1–5 and 16–20, and with themesenchymal status of breast tu-
mors (Fig. 4; Xu et al. 2014). hnRNPM plays a role in both
EMT induction and maintenance, at least in part by potenti-
ating TGFβ signaling and controlling CD44 isoform switch-
ing from the CD44 variable (CD44v) exon-8-containing
splice isoform to the CD44s isoform (Xu et al. 2014).
Splicing factor hnRNPH, which is up-regulated in glio-
blastoma multiforme, controls splicing of MADD, a death-
domain adaptor protein, to generate an antagonistic anti-
apoptotic isoform that promotes survival and proliferation,
and similarly mediates the splicing switch to a ligand-inde-
pendent, constitutively active variant of the tyrosine kinase
receptorMST1R (Ron), which promotes migration and inva-
sion (Fig. 4; Lefave et al. 2011).
ESRP1 and 2—epithelial splicing regulator
protein 1 and 2
ESRP1 (epithelial splicing regulatory protein 1, also known as
RBM35) and ESRP2 (epithelial splicing regulatory protein 2,
also known as RBM35B) are two structurally related splicing
factors, encoded by genes on Chr. 8 and Chr. 16, respectively,
and expressed specifically in epithelial cells (Fig. 4; Warzecha
et al. 2009a). The mammalian ESRPs and their orthologs
in chicken, D. melanogaster, and C. elegans comprise three
RRMs and display significant phylogenetic sequence conser-
vation within these domains, particularly within the first
RRM (Warzecha et al. 2009a). Mice with ablation of Esrp1
develop cleft lip and palate, whereas tissue-specific ablation
in the epidermis revealed ESRP1’s requirement for establish-
ing a proper skin barrier (Bebee et al. 2015). Loss of both
Esrp1 and Esrp2 results in widespread developmental defects
(Bebee et al. 2015). ESRPs regulate alternative splicing events
associated with epithelial cell phenotypes, and both proteins
are down-regulated during the epithelial-mesenchymal tran-
sition (EMT) (Warzecha et al. 2009a). ESRP splicing targets
are enriched in genes involved in cytoskeletal dynamics, cell
motility, cell–cell junctions, and pathways involved in EMT,
including CD44, ENAH, and FGFR2 isoforms (Warzecha
et al. 2009a,b; Shapiro et al. 2011; Dittmar et al. 2012).
During oral squamous cell carcinogenesis, ESRPs are up-reg-
ulated relative to their levels in normal epithelium, but down-
regulated in invasive fronts (Ishii et al. 2014). Importantly,
ESRPs are expressed in the lymph nodes, where carcinoma
cells metastasize and colonize (Ishii et al. 2014). In head
and neck carcinoma cell lines, ESRP1 and ESRP2 suppress
cancer cell motility through distinct mechanisms: ESRP1
KD affects the dynamics of the actin cytoskeleton through
induction of RAC1 splicing isoforms, whereas ESRP2 KD at-
tenuates cell-cell adhesion through increased expression of
EMT-associated transcription factors (Ishii et al. 2014). In
addition, ectopic expression of ESRP1 suppresses the malig-
nant phenotypes of colon and breast cancer cells, suggesting
that ESRP1 is a tumor suppressor (Leontieva and Ionov
2009; Horiguchi et al. 2012). In contrast, high levels of
ESRP1 expression are associated with lower survival rate in
breast cancer patients (Yae et al. 2012). These paradoxical
findings may reflect yet unappreciated differences between
the tumor subtypes or in the experimental models, which
should be further characterized in detail. Thus, ESRP1 is like-
ly to play a dual role during tumor progression, with the po-
tential to act either as a positive or a negative regulator.
RBFOX2—RNA binding protein, Fox-2 homolog
The RBFOX family of splicing regulators includes three
mammalian paralogs, RBFOX1 (A2BP1), RBFOX 2
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(RBM9), and RBFOX3 (NeuN), which control tissue-specific
alternative splicing of exons in brain, muscle, epithelial, and
mesenchymal cells, as well as in embryonic stem cells
(Kuroyanagi 2009). RBFOX proteins have a single RRM,
highly homologous among the three paralogs, and their
binding sites are exceptionally highly conserved in sequence
(UGCAUG) and position across vertebrate evolution (Sun
et al. 2012). Mutations or deletions in RBFOX1 and
RBFOX3 are found in epilepsy patients (Bhalla et al. 2004;
Lal et al. 2013a,b), whereas copy-number variations in
RBFOX1 are associated with autism spectrum disorders
and spinocerebellar ataxias (Bill et al. 2013; Weyn-Vanhen-
tenryck et al. 2014). Mouse models with Rbfox KO or KD
show extensive defects in neuronal and muscle physiology,
suggesting that these proteins play key roles in normal devel-
opment (Gehman et al. 2011, 2012). A role for RBFOX2
in cancer has also been proposed. Its levels are significantly
lower in epithelial ovarian cancer than in normal tissue (Ven-
ables et al. 2009). In breast cancer, alternative splicing events
occurring in cell lines from the claudin-low subtype are en-
riched in the RBFOX2 binding motif (Fig. 4; Lapuk et al.
2010). RBFOX2-regulated splicing events were also identified
in multiple solid tumor types, including breast, colon, and
pancreatic tumors (Danan-Gotthold et al. 2015). RBFOX2
was identified as one of the potential drivers of themesenchy-
mal splicing signature in a mammary cell line, following in-
duction of Twist expression (Shapiro et al. 2011). In this
context, the loss of RBFOX2 in mesenchymal cells leads to
a partial reversion of the epithelial phenotype, with reduced
levels of vimentin, changes in morphology, and restrictedmi-
gration (Shapiro et al. 2011). Furthermore RBFOX2 regulates
events that differ between epithelial and mesenchymal cancer
cell lines (Venables et al. 2013). Thus, RBFOX2 may be im-
portant to specify the mesenchymal tissue-specific splicing
profiles both in normal and in cancer tissues.
RBM5, 6, and 10—RNA binding motif
protein 5, 6, and 10
RBM5, RBM6, and RBM10 are highly homologous RNA-
binding proteins that share 30–50% amino-acid sequence
identity (Fig. 4; Bechara et al. 2013). They comprise two
RRMs and an RS-domain, as well as a zing-finger domain,
a G-patch domain, and a nuclear localization signal (Bechara
et al. 2013). The genes encoding RBM5 and RBM6map to the
Chr. 3p21.3 region, which is frequently deleted in heavy
smokers, in lung cancer, and in other tissue carcinomas
(Angeloni 2007). RBM5 protein levels are down-regulated
in 75% of primary lung cancers (Oh et al. 2002), as well as
in prostate and breast cancer samples (Zhao et al. 2012).
Down-regulation of RBM5 is considered to be one molecular
signature associated with metastasis of various solid tumors
(Ramaswamy et al. 2003). On the other hand, overexpression
of RBM5 in breast cancer samples was also reported (Rintala-
Maki et al. 2007), paradoxically suggesting that both up- and
down-regulation of RBM5 can play a role in tumor progres-
sion. RBM6 and 10 also show altered expression in breast
cancer (Rintala-Maki et al. 2007). Overexpression of RBM5
in various cell lines leads to growth arrest, apoptosis, and de-
layed tumor growth when cells are injected into nude mice
(Mourtada-Maarabouni and Williams 2002; Oh et al. 2002,
2006; Mourtada-Maarabouni et al. 2003). RBM5-mediated
apoptosis is associated with up-regulation of the pro-apopto-
tic protein BAX and down-regulation of the anti-apoptotic
proteins BCL-2 and BCL-XL (Mourtada-Maarabouni and
Williams 2002; Oh et al. 2006; Sutherland et al. 2010).
RBM5/6 and RBM10 antagonistically regulate proliferation
of breast and lung cancer cells, and display distinct positional
effects on alternative splicing regulation (Bechara et al. 2013).
The Notch pathway regulator NUMB is a key splicing target
of RBM5, 6, and 10, which contributes to their role in colony
formation in vitro and in tumor xenograft growth in vivo
(Bechara et al. 2013). Finally, RBM10 is also among the
most frequently mutated genes in lung adenocarcinoma
(Imielinski et al. 2012). The RBM10 mutations identified in
patients disruptNUMB splicing regulation and promote pro-
liferation of cancer cell lines (Bechara et al. 2013; Hernandez
et al. 2016).
QKI—quaking KH domain containing RNA binding
Quaking KH domain containing RNA binding (QKI) protein
belongs to the STAR (signal transduction and activation of
RNA) family of RNA-binding proteins (Fig. 4; for review,
see Darbelli and Richard 2016). QKI has been implicated in
the regulation of myocyte and oligodendrocyte differentia-
tion, as well as in endothelial-cell function (Darbelli and
Richard 2016). QKI haploinsufficiency is associated with
the 6q terminal deletion syndrome, which is characterized
by intellectual disabilities (Darbelli and Richard 2016). QKI
is also frequently down-regulated in lung adenocarcinoma,
squamous cell carcinoma, and large cell carcinoma, com-
pared with normal lung, and its down-regulation is signifi-
cantly associated with poor prognosis (Zong et al. 2014).
QKI expression is also reduced in oral squamous cell carcino-
ma, compared to normal mucosa (Lu et al. 2014), as well as in
prostate cancer samples, at least in part due to the high levels
of promoter methylation (Zhao et al. 2014). QKI is highly ex-
pressed in benign prostatic hyperplasia, but not in carcino-
matous tissue (Zhao et al. 2014). In addition, the decrease
in QKI expression closely correlates with the Gleason score,
poor differentiation, degree of invasion, lymph-node metas-
tasis, distant metastasis, tumor grading, and poor survival
(Zhao et al. 2014). QKI overexpression impairs proliferation
and transformation of lung and prostate cancer cells (Zhao
et al. 2014; Zong et al. 2014), as well as reduces cancer
stem cell sphere formation and stem-cell-associated gene ex-
pression in oral cancer cells (Lu et al. 2014). In a tumor-im-
plantation nude-mouse model, QKI expression significantly
reduces the tumor-initiation rate, tumor size, and lung-
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metastasis rate, whereas QKI KD has the opposite effects (Lu
et al. 2014; Zong et al. 2014). QKI expression is also down-
regulated in lung, colon, and breast tumors, but is up-regu-
lated in kidney cancer, and QKI-regulated splicing events
are altered in the corresponding tumor types (Danan-
Gotthold et al. 2015). QKI regulates splicing of NUMB,
which in turn suppresses cell proliferation and prevents the
activation of the Notch signaling pathway (Zong et al.
2014). QKI may also directly regulate SOX2 expression via
specific binding to its mRNA 3′UTR in a cis-element-depen-
dent way (Lu et al. 2014). Recently, MYB-QKI fusions were
identified as a specific and single candidate-driver event in
angiocentric gliomas (Bandopadhayay et al. 2016). In vitro
and in vivo functional studies demonstrated that MYB-
QKI rearrangements promote tumorigenesis through three
mechanisms: MYB activation by truncation, enhancer trans-
location driving aberrant MYB-QKI expression, and hemizy-
gous loss of the QKI tumor suppressor (Bandopadhayay et al.
2016).
REGULATION OF THE SPLICING
MACHINERY IN TUMORS
How changes in splicing-factor levels occur in human tumors
remains poorly understood. In the absence of genomic alter-
ations at loci encoding splicing regulators, alterations in
splicing-factor expression likely result from changes in tran-
scriptional or post-transcriptional regulation, as well as in
signaling pathways.
Splicing-factor regulation by the transcription
factor MYC
A link between the transcription factor oncoprotein MYC
and the splicing machinery has emerged in the past few years.
Genes encoding several splicing factors, such as SRSF1,
HNRNPA1, HNRNPA2, or PTB, were shown to be direct
transcriptional targets of MYC (Figs. 1, 3; David et al. 2010;
Anczukow et al. 2012; Das et al. 2012). Furthermore,
SRSF1 not only contributes to MYC’s oncogenic activity
(Das et al. 2012), but also cooperates with MYC in transfor-
mation, promoting the formation of more aggressive breast
tumors (Anczukow et al. 2012). In addition, two recent stud-
ies revealed that components of the spliceosome, such as
PRMT5 and BUD31, are essential for MYC to function as
an oncogene in lymphoma and breast cancer, respectively
(Hsu et al. 2015; Koh et al. 2015). As MYC is the most fre-
quently amplified oncogene in human cancers and plays a
crucial role in transformation, therapies that exploit the spli-
ceosome would be very attractive. Both studies uncovered an
essential role of the splicing machinery in MYC-driven trans-
formation, and identifiedmultiple associated abnormal splic-
ing events, including intron retention (Hsu et al. 2015; Koh
et al. 2015). Interestingly, MYC appears to alter splicing by
somewhat different mechanisms in lymphomagenesis versus
breast cancer. In the former context, MYC hyperactivation
affects the levels of specific splicing regulators (Koh et al.
2015), whereas in the latter context, it promotes a global in-
crease in pre-mRNA levels (Hsu et al. 2015), although up-
regulation of particular splicing regulators was also previous-
ly reported (David et al. 2010; Anczukow et al. 2012; Das et al.
2012). These ostensibly different findings suggest that many
of the splicing changes associated with cancer are context-
dependent.
Post-transcriptional regulation of SRSFs
SRSFs are essential genes whose expression is tightly regulated
at the post-transcriptional level. For example, SRSF1 or
SRFS2 regulate splicing of introns in the 3′UTR of their
own pre-mRNA; splicing out of these introns introduces an
exon–exon junction downstream from the normal stop co-
don, which targets the mRNA to NMD (Sureau et al. 2001;
Lareau et al. 2007a,b). This mechanism is highly conserved
and shared by other SR proteins (Sureau et al. 2001; Lareau
et al. 2007a,b; Lareau and Brenner 2015). SRSF1 autoregula-
tion can also occur via nuclear retention of alternative SRSF1
transcript variants or regulation of the translational efficiency
of other variants (Sun et al. 2010). Autoregulation of SR
proteins serves as a negative feedback loop, in which in-
creased SR protein levels promote an increase in unproduc-
tive spliced variants of their own transcripts. Furthermore,
several miRNAs targeting SRSF1mRNA have been identified,
including mir-7, miR-28, miR-505, miR-10a, and miR-10b
(Verduci et al. 2010; Wu et al. 2010; Meseguer et al. 2011).
Finally, SRSF1 expression is also regulated at the level of splic-
ing by the splicing factor Sam68 (Valacca et al. 2010). In re-
sponse to ERK1/2 signaling, Sam68 switches splicing of the
SRSF1 transcript from the NMD-targeted isoforms to the
major, translatable isoform, thus resulting in an increase in
SRSF1 protein levels. Sam68-mediated SRSF1 overexpression
is associated with oncogenic phenotypes, such as increased
cell-proliferation, anchorage-independent growth, cell mo-
tility and invasion, and epithelial–mesenchymal transition
in colon cancer cell lines (Valacca et al. 2010). Thus, SRSF1
transcript levels are fine-tuned by various post-transcription-
al mechanisms, though the precise contributions of each step
in response to various stimuli remain to be determined.
SR protein regulation by phosphorylation
SR protein localization and activity are regulated by a dynam-
ic cycle of phosphorylation/dephosphorylation, mostly at
serine residues within the RS-domain (for a detailed review,
see Long and Caceres 2009). For example, phosphorylation of
SRSF1’s RS domain enhances protein–protein interactions
with other RS-domain-containing splicing factors, such as
U1–70K (Xiao and Manley 1997), whereas dephosphoryla-
tion of SR and SR-related proteins is required for splicing
catalysis (Tazi et al. 1993; Cao et al. 1997). The SR protein
Splicing-factor alterations in cancers
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kinase family (SRPK) (Gui et al. 1994; Wang et al. 1998), Clk/
Sty kinase family (Colwill et al. 1996) and topoisomerase I
(Rossi et al. 1996) have been identified as the main regulators
of SR protein phosphorylation. A hypo-phosphorylated RS
domain is required for the interaction of shuttling SR pro-
teins with the TAP/NFX1 nuclear export receptor (Huang
et al. 2004), whereas the RS domain needs to be rephosphory-
lated before SR proteins can return to the nucleus (Ding et al.
2006). Dephosphorylation also plays an important role in
sorting SR proteins in the nucleus, where shuttling SR pro-
teins and nonshuttling SR proteins are recycled via different
recycling pathways (Lin et al. 2005). In the cytoplasm,
dephosphorylation of the RS domain enhances mRNA bind-
ing by SRSF1 and contributes to its stimulatory role in trans-
lation (Sanford et al. 2005). The regulation of SR protein
phosphorylation has been implicated in the control of can-
cer-associated splicing events. For example, growth-factor-
induced alternative splicing of the fibronectin EDA exon in-
volves phosphorylation of SRSF1 and SRSF7 by AKT kinase
(Blaustein et al. 2004). This effect is most likely indirect
and occurs via SRPKs. Indeed, AKT was shown to activate
SRPKs in response to EGF-signaling, thus leading to en-
hanced SRPK nuclear translocation and SR protein phos-
phorylation (Zhou et al. 2012). Multiple components of
the AKT pathway function as oncogenes or tumor sup-
pressors, and overexpression of SRPK1 is seen in multiple tu-
mor types (Hayes et al. 2006, 2007; Plasencia et al. 2006;
Krishnakumar et al. 2008; Amin et al. 2011); however, how
perturbations in phosphorylation processes lead to changes
in splicing-factor activity in human tumors remains to be
defined.
TARGETING ALTERNATIVE-SPLICING ALTERATIONS
FOR CANCER THERAPY
The idea of targeting the spliceosome is not new, and the first
general splicing inhibitors were initially identified in the late
1990s, during the course of characterizing certain anti-tumor
drugs (for review, see Bonnal et al. 2012). However, improve-
ments in RNA-targeting therapeutics and in particular in
antisense-oligonucleotide pharmacology, as well as a better
understanding of the mode of action of these molecules,
have created novel therapeutic opportunities. Two concep-
tually different approaches to splicing inhibition are currently
being tested.
Blocking splicing-factor activity with small-molecule
inhibitors
The first approach is to target general components of the
splicing machinery and inhibit splicing at a global level,
e.g., using small-molecule inhibitors of the SF3B complex,
or of kinases that phosphorylate SR proteins (Bonnal et al.
2012). These drugs inhibit very basic steps in splice-site rec-
ognition, lack splicing-target specificity, and can potentially
have broad cytotoxic effects. However, several studies have
reported that cancer cells are more sensitive to these drugs,
compared to normal cells (Bonnal et al. 2012), suggesting
that general inhibition of splicing could be a viable anti-tu-
mor strategy. For example, SF3B1 inhibitors, such as spli-
ceostatin A, pladienolide-B, GEX1A, and E1707, partially
inhibit splicing in cultured cells and animal models, and
show selective action, i.e., greater potency, on tumor cells
(for review, see Ohe and Hagiwara 2015). Thus SF3B1 in-
hibitors are currently being evaluated in the context of splic-
ing-factor mutations in preclinical models of MDS (Lee et
al. 2016).
Another way to block splicing-factor activity is to inhibit
the regulatory kinases that phosphorylate the SR proteins
(Ohe and Hagiwara 2015). For example, inhibition of
Cdc2-like kinase 1 (CLK1), dual-specificity-tyrosine-phos-
phorylation-regulated kinase 1A (DYRK1A), or SR protein-
specific kinase (SRPK) affects alternative splicing and induces
exon skipping of SR-regulated exons in cell cultures (Ohe and
Hagiwara 2015).
Exon-specific splicing modulation
An alternative approach to target splicing alterations is to
directly target a tumor-specific splicing event, e.g., by using
antisense oligonucleotides that bind to a transcript in a se-
quence-specific manner to redirect splicing (for review, see
Kole et al. 2012). Briefly, antisense oligonucleotides are short
single-stranded nucleic-acidmolecules with various chemical
modifications—compared to RNA or DNA—that bind to
complementary sequences on the target pre-mRNA in the
nucleus. The target sequences can be, e.g., splice sites, splic-
ing enhancers, or splicing silencers, which are normally rec-
ognized by the core splicing machinery or by a particular
regulatory splicing factor (activator or repressor). Thus,
such antisense compounds can be used either to promote
or inhibit a splicing event in a target-specific manner. This
approach is expected to have few off-targets effects—provid-
ed that unique complementary sequences in the transcrip-
tome are targeted—and with appropriate target selection, it
might be more tumor-specific, compared to general splicing
inhibitors. However, identifying a key splicing event, or more
likely a set of splicing events, required for transformation and
tumor maintenance, will require a concerted effort.
Finally, small-molecules that can specifically modulate a
single alternative splicing event are currently being investigat-
ed as an alternative to antisense-oligonucleotide therapies.
For example, several groups identified compounds that en-
hance SMN2 exon 7 splicing to promote the production of
a full-length SMN protein (Hastings et al. 2009; Naryshkin
et al. 2014; Palacino et al. 2015), an approach with therapeu-
tic potential for spinal muscular atrophy. Likewise, small
molecules that promote the inclusion of exon 20 in the
IKBKAP pre-mRNA have been reported, and may have ther-
apeutic utility for familial dysautonomia (Yoshida et al.
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2015). However, it is still unknown to what extent this type of
strategy may be broadly applicable to other splicing events.
These molecules were initially identified using cell-based re-
porter screens, and while potential mechanisms of action
have been proposed, additional work will be required to un-
derstand what degree of target specificity is achievable, and to
what extent these approaches are generalizable.
In summary, splicing-factor alterations detected in human
tumors are a growing area of interest in cancer research, and
represent potential targets for personalized cancer therapies.
However, the precise roles of splicing factors in normal tissue
physiology and the consequences of their dysregulation in
disease are still underexplored. A better understanding of
the cell-type specificity and functions of cancer-associated
splicing factors will be crucial for the development of new
therapeutic strategies.
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